The evolution of prostate cancer therapy: targeting the androgen receptor.
Division of Hematology and Oncology, Department of Medicine, George Washington University Medical Center , Washington, DC , USA.
Jeanny B
JB
Aragon-Ching
abiraterone acetate; androgen receptor; castration-resistant prostate cancer; enzalutamide; prostate cancer